FDA Oks new therapy to prevent hemophilia bleeding

Published



WASHINGTON (AP) — The Food and Drug Administration has approved the first hemophilia B treatment designed to decrease frequency of injections to prevent the excessive bleeding the clotting disorder causes.

The medicine, Alprolix (all-PRO’licks), is for preventing or shortening bleeding episodes in adults and children with hemophilia B, the second-most common type. It affects about 3,300 Americans, mostly males.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.